Fusion Antibodies (LON:FAB) Announces Earnings Results

Fusion Antibodies (LON:FAB) released its earnings results on Monday. The company reported GBX (1.20) earnings per share for the quarter, Digital Look Earnings reports. Fusion Antibodies had a negative net margin of 91.92% and a negative return on equity of 210.32%.

Fusion Antibodies Stock Down 14.5%

Fusion Antibodies stock opened at GBX 9.70 on Monday. Fusion Antibodies has a twelve month low of GBX 9.10 and a twelve month high of GBX 21. The company has a debt-to-equity ratio of 92.42, a quick ratio of 2.36 and a current ratio of 1.80. The firm has a market cap of £12.14 million, a PE ratio of -6.47 and a beta of 1.24. The firm’s 50 day moving average price is GBX 10.89 and its two-hundred day moving average price is GBX 12.20.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.